Abstract
Deep brain stimulation (DBS) is an established therapy for patients with Parkinson’s disease. In silico computer models for DBS allow to pre-select a set of potentially optimal stimulation parameters. If efficacious, they could further carry insight into the mechanism of action of DBS and foster the development of more efficient stimulation approaches. In recent years, the focus has shifted towards DBS-induced firing in myelinated axons, deemed particularly relevant for the external modulation of neural activity. We use the concept of pathway activation modeling, which incorporates advanced volume conductor models and anatomically authentic fiber trajectories to estimate DBS-induced action potential initiation in anatomically plausible pathways that traverse in close proximity to targeted nuclei. We apply the method on a retrospective dataset with the aim of providing a model-based prediction of clinical improvement following DBS (as measured by the motor part of the Unified Parkinson’s Disease Rating Scale). Based on differences in outcome and activation rates for two DBS protocols in a training cohort, we compute a theoretical 100% improvement profile and enhance it by analyzing the importance of profile matching for individual pathways. Finally, we validate the performance of our profile-based predictive model in a test cohort. As a result, we demonstrate the clinical utility of pathway activation modeling in the context of motor symptom alleviation in Parkinson’s patients treated with DBS.
Competing Interest Statement
J.V. have business relationships with Medtronic, Abbott, and Boston Scientific, which are makers of DBS devices, outside the submitted work. A.A.K. reports personal fees and non-financial support from Medtronic, personal fees from Boston Scientific, grants and personal fees from Abbott, outside the submitted work. M.R. reports grant support and honoraria for speaking from Medtronic and Boston Scientific, outside the submitted work. A.H. reports lecture fees for Medtronic and Boston Scientific and is a consultant for AlphaOmega. G.R.W received travel expenses and attendance fees by Boston Scientific and Ipsen Pharma. K.B., N.L., C.N., J.R., H.E. and U.v.R. have nothing to disclose.
Funding Statement
Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - SFB 1270/1 - 299150580 and TRR 295 - 424778381. A.H. was further supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Emmy Noether Stipend - 410169619 as well as Deutsches Zentrum für Luft- und Raumfahrt (DynaSti grant within the EU Joint Programme Neurodegenerative Disease Research, JPND). A.H. is participant in the BIH-Charité Clinician Scientist Program funded by the Charité - Universitätsmedizin Berlin and the Berlin Institute of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The collection and analysis of all patient data from the training cohort was approved by the Local Ethics committee of Charité - Universitätsmedizin Berlin (master vote EA2/186/18). The collection and analysis of all patient data from the test cohort was approved by the institutional review board of the University Hospital of Würzburg (registration no. 150/15 amendment).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* konstantin.butenko{at}charite.de, ursula.van-rienen{at}uni-rostock.de
Data Availability
The data that support the findings of this study are available from the first corresponding author.
